Oscar Health (OSCR) EV to EBITDA (2021 - 2026)

Oscar Health (OSCR) has reported EV to EBITDA for 6 consecutive years, with 1.94 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA rose 64.05% year-over-year to 1.94; the trailing twelve-month figure through Jun 2026 stood at 1.82 (down 114.31% YoY), and the FY2025 full-year result was 0.57, down 85.78% from the prior year.
• EV to EBITDA improved to 1.94 in Q2 2026 per OSCR's latest filing, from 5.36 in the prior quarter.
• Across five years, EV to EBITDA topped out at 55.3 in Q3 2024 and bottomed at 61.95 in Q1 2023.
• Historically, EV to EBITDA has averaged 1.11 across 5 years, with a median of 0.57 in 2024.
• The sharpest annual moves came in 2022 and 2024: EV to EBITDA surged 6273.75% in 2022, then slumped 1842.63% in 2024.
• Over 5 years, EV to EBITDA stood at 11.27 in 2022, then sank by 80.44% to 2.21 in 2023, then plunged by 1842.63% to 38.43 in 2024, then jumped by 101.06% to 0.41 in 2025, then plunged by 575.02% to 1.94 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 1.94, 5.36, and 0.41 for Q2 2026, Q1 2026, and Q4 2025 respectively.